Cargando…

Recent Advances in Manufacturing Innovative Stents

Cardiovascular diseases are the most distributed cause of death worldwide. Stenting of arteries as a percutaneous transluminal angioplasty procedure became a promising minimally invasive therapy based on re-opening narrowed arteries by stent insertion. In order to improve and optimize this method, m...

Descripción completa

Detalles Bibliográficos
Autores principales: Beshchasna, Natalia, Saqib, Muhammad, Kraskiewicz, Honorata, Wasyluk, Łukasz, Kuzmin, Oleg, Duta, Oana Cristina, Ficai, Denisa, Ghizdavet, Zeno, Marin, Alexandru, Ficai, Anton, Sun, Zhilei, Pichugin, Vladimir F., Opitz, Joerg, Andronescu, Ecaterina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7238261/
https://www.ncbi.nlm.nih.gov/pubmed/32294908
http://dx.doi.org/10.3390/pharmaceutics12040349
_version_ 1783536505354977280
author Beshchasna, Natalia
Saqib, Muhammad
Kraskiewicz, Honorata
Wasyluk, Łukasz
Kuzmin, Oleg
Duta, Oana Cristina
Ficai, Denisa
Ghizdavet, Zeno
Marin, Alexandru
Ficai, Anton
Sun, Zhilei
Pichugin, Vladimir F.
Opitz, Joerg
Andronescu, Ecaterina
author_facet Beshchasna, Natalia
Saqib, Muhammad
Kraskiewicz, Honorata
Wasyluk, Łukasz
Kuzmin, Oleg
Duta, Oana Cristina
Ficai, Denisa
Ghizdavet, Zeno
Marin, Alexandru
Ficai, Anton
Sun, Zhilei
Pichugin, Vladimir F.
Opitz, Joerg
Andronescu, Ecaterina
author_sort Beshchasna, Natalia
collection PubMed
description Cardiovascular diseases are the most distributed cause of death worldwide. Stenting of arteries as a percutaneous transluminal angioplasty procedure became a promising minimally invasive therapy based on re-opening narrowed arteries by stent insertion. In order to improve and optimize this method, many research groups are focusing on designing new or improving existent stents. Since the beginning of the stent development in 1986, starting with bare-metal stents (BMS), these devices have been continuously enhanced by applying new materials, developing stent coatings based on inorganic and organic compounds including drugs, nanoparticles or biological components such as genes and cells, as well as adapting stent designs with different fabrication technologies. Drug eluting stents (DES) have been developed to overcome the main shortcomings of BMS or coated stents. Coatings are mainly applied to control biocompatibility, degradation rate, protein adsorption, and allow adequate endothelialization in order to ensure better clinical outcome of BMS, reducing restenosis and thrombosis. As coating materials (i) organic polymers: polyurethanes, poly(ε-caprolactone), styrene-b-isobutylene-b-styrene, polyhydroxybutyrates, poly(lactide-co-glycolide), and phosphoryl choline; (ii) biological components: vascular endothelial growth factor (VEGF) and anti-CD34 antibody and (iii) inorganic coatings: noble metals, wide class of oxides, nitrides, silicide and carbide, hydroxyapatite, diamond-like carbon, and others are used. DES were developed to reduce the tissue hyperplasia and in-stent restenosis utilizing antiproliferative substances like paclitaxel, limus (siro-, zotaro-, evero-, bio-, amphi-, tacro-limus), ABT-578, tyrphostin AGL-2043, genes, etc. The innovative solutions aim at overcoming the main limitations of the stent technology, such as in-stent restenosis and stent thrombosis, while maintaining the prime requirements on biocompatibility, biodegradability, and mechanical behavior. This paper provides an overview of the existing stent types, their functionality, materials, and manufacturing conditions demonstrating the still huge potential for the development of promising stent solutions.
format Online
Article
Text
id pubmed-7238261
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-72382612020-06-02 Recent Advances in Manufacturing Innovative Stents Beshchasna, Natalia Saqib, Muhammad Kraskiewicz, Honorata Wasyluk, Łukasz Kuzmin, Oleg Duta, Oana Cristina Ficai, Denisa Ghizdavet, Zeno Marin, Alexandru Ficai, Anton Sun, Zhilei Pichugin, Vladimir F. Opitz, Joerg Andronescu, Ecaterina Pharmaceutics Review Cardiovascular diseases are the most distributed cause of death worldwide. Stenting of arteries as a percutaneous transluminal angioplasty procedure became a promising minimally invasive therapy based on re-opening narrowed arteries by stent insertion. In order to improve and optimize this method, many research groups are focusing on designing new or improving existent stents. Since the beginning of the stent development in 1986, starting with bare-metal stents (BMS), these devices have been continuously enhanced by applying new materials, developing stent coatings based on inorganic and organic compounds including drugs, nanoparticles or biological components such as genes and cells, as well as adapting stent designs with different fabrication technologies. Drug eluting stents (DES) have been developed to overcome the main shortcomings of BMS or coated stents. Coatings are mainly applied to control biocompatibility, degradation rate, protein adsorption, and allow adequate endothelialization in order to ensure better clinical outcome of BMS, reducing restenosis and thrombosis. As coating materials (i) organic polymers: polyurethanes, poly(ε-caprolactone), styrene-b-isobutylene-b-styrene, polyhydroxybutyrates, poly(lactide-co-glycolide), and phosphoryl choline; (ii) biological components: vascular endothelial growth factor (VEGF) and anti-CD34 antibody and (iii) inorganic coatings: noble metals, wide class of oxides, nitrides, silicide and carbide, hydroxyapatite, diamond-like carbon, and others are used. DES were developed to reduce the tissue hyperplasia and in-stent restenosis utilizing antiproliferative substances like paclitaxel, limus (siro-, zotaro-, evero-, bio-, amphi-, tacro-limus), ABT-578, tyrphostin AGL-2043, genes, etc. The innovative solutions aim at overcoming the main limitations of the stent technology, such as in-stent restenosis and stent thrombosis, while maintaining the prime requirements on biocompatibility, biodegradability, and mechanical behavior. This paper provides an overview of the existing stent types, their functionality, materials, and manufacturing conditions demonstrating the still huge potential for the development of promising stent solutions. MDPI 2020-04-13 /pmc/articles/PMC7238261/ /pubmed/32294908 http://dx.doi.org/10.3390/pharmaceutics12040349 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Beshchasna, Natalia
Saqib, Muhammad
Kraskiewicz, Honorata
Wasyluk, Łukasz
Kuzmin, Oleg
Duta, Oana Cristina
Ficai, Denisa
Ghizdavet, Zeno
Marin, Alexandru
Ficai, Anton
Sun, Zhilei
Pichugin, Vladimir F.
Opitz, Joerg
Andronescu, Ecaterina
Recent Advances in Manufacturing Innovative Stents
title Recent Advances in Manufacturing Innovative Stents
title_full Recent Advances in Manufacturing Innovative Stents
title_fullStr Recent Advances in Manufacturing Innovative Stents
title_full_unstemmed Recent Advances in Manufacturing Innovative Stents
title_short Recent Advances in Manufacturing Innovative Stents
title_sort recent advances in manufacturing innovative stents
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7238261/
https://www.ncbi.nlm.nih.gov/pubmed/32294908
http://dx.doi.org/10.3390/pharmaceutics12040349
work_keys_str_mv AT beshchasnanatalia recentadvancesinmanufacturinginnovativestents
AT saqibmuhammad recentadvancesinmanufacturinginnovativestents
AT kraskiewiczhonorata recentadvancesinmanufacturinginnovativestents
AT wasylukłukasz recentadvancesinmanufacturinginnovativestents
AT kuzminoleg recentadvancesinmanufacturinginnovativestents
AT dutaoanacristina recentadvancesinmanufacturinginnovativestents
AT ficaidenisa recentadvancesinmanufacturinginnovativestents
AT ghizdavetzeno recentadvancesinmanufacturinginnovativestents
AT marinalexandru recentadvancesinmanufacturinginnovativestents
AT ficaianton recentadvancesinmanufacturinginnovativestents
AT sunzhilei recentadvancesinmanufacturinginnovativestents
AT pichuginvladimirf recentadvancesinmanufacturinginnovativestents
AT opitzjoerg recentadvancesinmanufacturinginnovativestents
AT andronescuecaterina recentadvancesinmanufacturinginnovativestents